Physician profile
Wael E Eid
NPI 1013936517
$30,770.22
in general payments reported to CMS, 2019-2025
59 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,705 · 2021: $1,030 · 2022: $1,997 · 2023: $2,021 · 2024: $2,707 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,496 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,496.45 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,593.91 | 2019-2025 | Repatha, Tepezza, Repatha |
| Dexcom, INC. | $1,312.54 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,246.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,104.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $754.87 | 2022-2025 | |
| Abbott Laboratories | $687.87 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $634.63 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $514.15 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $478.35 | 2019-2025 | Evkeeza |
| Insulet Corporation | $429.89 | 2019-2024 | Omnipod |
| Medtronic, INC. | $338.88 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $329.55 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $273.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.61 | 2019-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $182.96 | 2020-2022 |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.